Better overall lipid effects were seen in type 2 diabetes patients with coronary artery disease treated with metformin than those being treated with glipizide….

A total daily insulin dose of about 0.2 U/kg was optimal to cover the fast day, "although there is considerable variability between patients."…

A peptide called caerulein converted existing cells in the pancreas into insulin-generating beta cells….

Adequate glycemic control is 48% and health insurance coverage among Latino diabetics is 52.4%…. 

  Rudy Bilous MD, FRCP Richard Donnelly MD, PHD, FRCP, FRACP   The most common cause of type 1 diabetes (over 90% of cases) is T cell-mediated autoimmune destruction of the islet beta cells leading to a failure of insulin production. The exact aetiology is complex and still imperfectly understood. However, it …

Diabetes is a huge and growing problem, and the costs to society are high and escalating. In South and Central America, the number of people with diabetes will increase by 60% by 2035. The Top 5 countries for prevalence are: Puerto Rico, Nicaragua, Dominican Republic, Guatemala, and El Salvador. To …

SUDOSCAN: Early Identification of Peripheral Autonomic Neuropathies  SUDOSCAN+ is a test that provides an accurate evaluation of sweat gland function focusing on small nerve fibers within the peripheral nervous system innervating the sweat glands. SUDOSCAN+ measures the ability of the sweat glands to release chloride ions in response to an …

Diabetes Drug Empagliflozin (Jardiance- SGLT-2) Wins FDA Approval. More news in next week’s issue. GSK’s Tanzeum (GLP-1 agonist) is now available in pharmacies in the U.S.

Women who ate 5 grams daily of green-plant membranes purified from spinach lost more weight and had fewer urges to eat unhealthy foods than did those given a placebo, Swedish researchers reported. Women who consumed green-plant membranes also had higher secretions of the satiety hormone GLP-1. Green-plant membranes slow fat …

Xultophy, a type 2 diabetes candidate, received a positive opinion from the European Medicines Agency’s Committee. Xultophy is a once-daily single injection combination of insulin degludec and liraglutide. The CHMP recommended the approval of Xultophy for the treatment of adults suffering from type 2 diabetes in combination with glucose-lowering oral …